沙美特罗替卡松粉剂吸入治疗70岁以上中、重度AECOPD临床疗效观察

Clinical observation of the efficacy of inhaling salmeterol and fluticasone powder in the treatment of chronic obstructive pulmonary disease with acute exacerbation in patients aged seventy years or older

目的观察沙美特罗替卡松粉剂(舒利迭)吸入用于治疗70岁以上中重度慢性阻塞性肺疾病急性加重期(AECO-PD)的疗效。方法将108例70岁以上中、重度AECOPD患者随机分为沙美特罗/替卡松粉剂吸入组、硫酸沙丁胺醇气雾剂吸入组,对两组治疗前后的FEV1、FEV1/FVC、FEV1占预计值百分比及临床症状改善情况进行比较。结果使用舒利迭组患者在治疗早期肺功能即有明显改善,随着使用时间延长,肺功能改善得到逐渐提高。使用硫酸沙丁胺醇组,治疗初期,临床症状迅速改善,随着治疗时间延长,疗效有所下降,肺功能无明显改善。结论舒利迭治疗70岁以上中、重度AECOPD,临床改善明显,能持续改善患者的肺功能。

Objective To observe the efficacy of inhaling salmeterol and fluticasone powder in the treatment of chronic obstructive pulmonary with acute exacerbation （AECOPD） in patients aged seventy years or older. Methods 108 patients in hospital with AECOPD were divided into two groups： the Salmeterol/Fluticasone Powder group, and the Salbutamol Sulfate group. EFV1 , FEV1/FVC, FEV1 percentage of predicted Value and clinical efficacy were compared. Between the groups. Results The lung function improved significantly and increased steadily with inhaling salmeterol and fluticasone powder. The lung function of salbutamol sulfate group improved rapidly after one week, while its lung function improved little after 4 weeks and three months. Conclusions The inhalation of salmeterol and fluticasone powder can rapidly and steadily improve the lung function of AECOPD in patients aged seventy years or older, and improve the patients＇ life quality.